Overview
The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.
Eligibility
Inclusion Criteria:
- Age ≥18 years
- Confirmed diagnosis of PV without symptomatic splenomegaly
- Indication and decision for treatment with ropeginterferon alfa-2b in accordance with current SmPC
- No prior treatment with ropeginterferon alfa-2b (Patients are allowed to be enrolled up to 6 weeks after their first dose of ropeginterferon alfa-2b but must still be on treatment at the time of enrollment.)
- Dated signature of informed consent form
- Participation in Patient-Reported Outcome (PRO) assessment in German language and completion of questionnaire at time of study enrollment
- Other criteria according to current Summary of Product Characteristics
Exclusion Criteria:
- Participation in an interventional clinical trial (except follow-up)
- Other contraindications according to current Summary of Product Characteristics